Volume : 08, Issue : 11, November – 2021
20.AN OVERVIEW OF UVEITIS MANAGEMENT APPROACHES
Uveitis may exist as a clinical manifestation of an underlying systemic disease or may represent an idiopathic entity, sometimes with a very characteristic pattern. Different forms of uveitis have been defined on the basis of three important variables: chronicity, anatomic location, and underlying aetiology. The evolving understanding of the immune system has resulted in a more targeted approach to manage patients with different forms of uveitis, although clearly this approach is at a very early stage. Diagnosis of uveitis is difficult. Etiologic investigations should take into account the epidemiology of uveitis and should focus on the most severe forms of the disease and those which can be treated. This study was undertaken to establish recommendations for the diagnosis of uveitis. We aimed to review the approaches in manage of uveitis, we conducted search through most important electronic databases, searching relevant studies concerning uveitis management. Although these biologic therapies have provided a larger armamentarium to treat uveitis, challenges remain. Uveitis is not a disease, but a manifestation of many potential systemic diseases that may have specific individual therapeutic targets. Identification and characterization of these underlying diseases are not always possible
Cite This Article:
Please cite this article in press Dina Abdulmannan, An Overview Of Uveitis Management Approaches, Indo Am. J. P. Sci, 2021; 08(11).
Number of Downloads : 10
1. Bose T, Diedrichs-Möhring M, Wildner G. Dry eye disease and uveitis: a closer look at immune mechanisms in animal models of two ocular autoimmune diseases. Autoimmun Rev 2016;15:1181–92.
2. Bose T, Diedrichs-Möhring M, Wildner G. Corrigendum to “dry eye disease and uveitis: a closer look at immune mechanisms in animal models of two ocular autoimmune diseases” [AUTREV 15-12 (2016) 1181-1192]. Autoimmun Rev 2017;16: 555.
3. Prete M, Dammacco R, Fatone MC, Racanelli V. Autoimmune uveitis: clinical, pathogenetic, and therapeutic features. Clin Exp Med 2015.
4. Gritz DC, Wong IG. Incidence and prevalence of uveitis in northern California; the northern California epidemiology of uveitis study. Ophthalmology 2004;111: 491–500 [discussion 500].
5. Rim TH, Kim SS, Ham D-I, S-Y Yu, Chung EJ, Lee SC, et al. Incidence and prevalence of uveitis in South Korea: a nationwide cohort study. Br J Ophthalmol 2017.
6. Sève P, Kodjikian L, Adélaïde L, Jamilloux Y. Uveitis in adults: what do rheumatologists need to know? Joint Bone Spine 2015;82:308–14.
7. Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, et al. Prevalence of noninfectious uveitis in the United States: a claims-based analysis. JAMA Ophthalmol 2016;134:1237–45.
8. Chang JH, Wakefield D. Uveitis: a global perspective. Ocul Immunol Inflamm 2002;10:263-79.
9. Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin 2005;45:1-13.
10. Hadjadj J, Dechartres A, Chapron T, Assala M, Salah S, Dunogué B, et al. Relevance of diagnostic investigations in patients with uveitis: Retrospective cohort study on 300 patients. Autoimmun Rev 2017;16:504–11.
11. De Parisot A, Kodjikian L, Errera M-H, Sedira N, Heron E, Pérard L, et al. Randomized controlled trial evaluating a standardized strategy for uveitis etiologic diagnosis (ULISSE). Am J Ophthalmol 2017;178:176–85.
12. Harper S, Chorich L, Foster C. Diagnosis of uveitis. WB: Saunders company. Philadelphia: Foster CS, Vitale A; 2002. p. 79–103.
13. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet 1989 May 20;1(8647):1093e6. PubMed PMID: 2566048.
14. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995 Dec;17(6):584e91. PubMed PMID: 8588225.
15. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005 May;123(5):634e41. PubMed PMID: 15883282.
16. Figueroa MS, Ciancas E, Orte L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol 2007 Jan-Feb;17(1):69e74. PubMed PMID: 17294385.
17. Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest 2003 Apr;111(8):1122e4. PubMed PMID: 12697731. Pubmed Central PMCID: 152947
18. Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013 Jan;40(1):74e9.
19. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005 Aug;52(8): 2447e51.
20. Matsuda J, Kaburaki T, Kobayashi S, et al. Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis. Jpn J Ophthalmol 2013 Jan;57(1):104e7.
21. Papadia M, Herbort CP. Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLAB27-related uveitis. Ocul Immunol Inflamm 2010 Dec;18(6):482e4.
22. Ally MR, Veerappan GR, Koff JM. Treatment of recurrent Crohn’s uveitis with infliximab. Am J Gastroenterol 2008 Aug; 103(8):2150e1.
23. Fries W, Giofre MR, Catanoso M, et al. Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. Am J Gastroenterol 2002 Feb;97(2):499e500.
24. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (Lond) 2005 Aug;19(8):841e5. P